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ABSTRACT
Objectives: To evaluate the effectiveness of a
pharmacist-led educational intervention to reduce the
use of high-risk abbreviations (HRAs) by healthcare
professionals.
Design: Quasi-experimental study consisting of a
single group before-and-after study design.
Setting: A public emergency hospital in Mecca, Saudi
Arabia.
Participants: 660 (preintervention) and then 498
(postintervention) handwritten physician orders,
medication administration records (MRAs) and
pharmacy dispensing sheets of 482 and 388 patients,
respectively, from emergency wards, inpatient settings
and the pharmacy department were reviewed.
Intervention: The intervention consisted of a series of
interactive lectures delivered by an experienced clinical
pharmacist to all hospital staff members and
dissemination of educational tools (flash cards,
printed list of HRAs, awareness posters) designed in
line with the recommendations of the Institute for Safe
Medical Practices and the US Food and Drug
Administration. The duration of intervention was from
April to May 2011.
Main outcome: Reduction in the incidence of HRAs
use from the preintervention to postintervention study
period.
Findings: The five most common abbreviations
recorded prior to the interventions were ‘IJ for
injection’ (28.6%), ‘SC for subcutaneous’ (17.4%),
drug name and dose running together (9.7%), ‘OD for
once daily’ (5.8%) and ‘D/C for discharge’ (4.3%). The
incidence of the use of HRAs was highest in discharge
prescriptions and dispensing records (72.7%) followed
by prescriptions from in-patient wards (47.3%). After
the intervention, the overall incidence of HRA was
significantly reduced by 52% (ie, 53.6% vs 25.5%;
p=0.001). In addition, there was a statistically
significant reduction in the incidence of HRAs across
all three settings: the pharmacy department (72.7% vs
39.3%), inpatient settings (47.3% vs 23.3%) and
emergency wards (40.9% vs 10.7%).
Conclusions: Pharmacist-led educational
interventions can significantly reduce the use of HRAs
by healthcare providers. Future research should
investigate the long-term effectiveness of such
educational interventions through a randomised
controlled trial.
INTRODUCTION
Medication errors are one of the major
causes of morbidity and mortality globally
and the most prevalent error in medical
care.1 These errors can occur while
Strengths and limitations of this study
▪ This is the first adequately powered study to
evaluate the effectiveness of a pharmacist-led
educational intervention to reduce the incidence
of high-risk abbreviations (HRAs) in an acute
care setting.
▪ A quasi-experimental design is best suited to
evaluate the effectiveness of an intervention
when conducting a randomised controlled trial is
not logistically feasible.
▪ Findings from the present study can assist pol-
icymakers to design policies to encourage safe
prescribing practices, thus reducing medication
errors.
▪ Quasi-experimental studies using a single group
before-and-after study design have poor internal
validity.
▪ We could not study the negative consequences
(eg, adverse drug reactions) of using HRAs and
the impact of reducing the incidence of using
HRAs on patient safety.
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prescribing, dispensing and administering medicines,
and most of them are preventable before they harm
patients.1 2 In hospitals, prescription and administration
errors are major threats to patient safety, with an esti-
mated incidence of 18.9–58.4%.1–5 There are many
reasons why medication errors occur, but in most cases
the errors can be linked to poor communication or tran-
scribing of the physician’s message. A contributing
factor in poor communication is the use of shorthand or
ambiguous abbreviations when writing prescriptions.5
Although the use of abbreviations is time saving, it does
not promote patient safety.6 7 In the USA, it has been
estimated that ∼5% of medication errors reported in
medical care are associated with the use of unsafe abbre-
viations leading to patient harm.8
Using shorthand or abbreviations in prescriptions
tends to become habitual practice if not discouraged.
On-the-job training or educational activities have been
shown to be a signiﬁcant help in the eradication of this
habit, with several studies having conﬁrmed that educa-
tional interventions are an effective tool for the improve-
ment of prescribing skills and, consequently, patient
safety.9–12 The Institute for Safe Medical Practices
(ISMP), together with the US Food and Drug
Administration (FDA), launched a nationwide educa-
tional campaign in 2006 to prevent the use of unsafe
and error-prone abbreviations in healthcare facilities
and developed a list of abbreviations, symbols and dose
designations that should be avoided while communicat-
ing all sorts of medical information.13 14 Subsequently,
many countries have followed suit. For instance, the New
South Wales Therapeutics Advisory Group (NSWTAG)
developed quality indicators according to the ISMP and
FDA recommendations to discontinue the use of abbre-
viations in Australian hospitals.15
Another concept that has been the focus of attention
in this regard is the increased emphasis on promoting a
safety culture during the teaching and training of
medical students and residents.7–9 Pharmacist-led educa-
tional interventions have been shown to improve safe
prescribing practices as well.12
Like any other country, medication errors are of great
concern in Saudi Arabia. Although the overall incidence
of medication errors in the Kingdom is not available,
studies have reported a prescribing error incidence of
8–56 per 100 medication orders in hospitalised
patients.16 17 In Saudi Arabia, the healthcare workforce
largely consists of expatriates educated and trained in
different countries including, but not limited to, the
UK, the USA, India, Pakistan, Egypt, Malaysia and the
Philippines. In addition, Saudi Arabia attracts more than
10 million pilgrims across the globe to visit holy
mosques each year who receive free medical treatment,
if required. Therefore, given the high number of
patients and diversity of healthcare workforce (in terms
of culture, language, clinical education and training),
healthcare providers may use high-risk abbreviations
(HRA) that could in turn lead to prescribing,
transcribing and administration errors, especially in
acute care facilities dealing with pilgrims. To the best of
our knowledge, no study has evaluated the extent of use
of HRAs in an acute care setting and impact of a
pharmacist-led educational intervention to reduce the
use of HRAs. Therefore, the aim of this study was to
evaluate the effectiveness of a pharmacist-led educa-
tional intervention to reduce the use of HRA by health-
care professionals (ie, doctors, nurses, pharmacists and
relevant assistants) in an acute care setting.
Method
A quasi-experimental study using a single group
before-and-after intervention design18 was conducted from
1 February 2011 to 1 July 2011. Although randomised con-
trolled trials (RCTs) are best suited to evaluate the effect-
iveness of an intervention,19 we were unable to design an
RCT due to the unavailability of a suitable control group.
The limitations of using a quasi-experimental design are
further discussed in the limitations section. The primary
outcome was reduction in the incidence of HRAs, as a pro-
portion of all prescriptions, from the preintervention to
postintervention period.
Settings
The study was conducted at an acute care facility spe-
cially designated for pilgrims visiting Majsid-Al-Haram
(The Grand Mosque), Mecca, Saudi Arabia. The hos-
pital on average provides emergency care to more than
5000 pilgrims a year. In addition to the outpatient
department and the pharmacy department, the hospital
has a 10-bed Coronary Care Unit (CCU) and 10-bed
Intensive Care Unit (ICU).
Identification of prescriptions with HRA
During the study period, electronic prescribing was
limited to inpatient physician orders only. All handwrit-
ten physician orders, medication administration records
(MRAs) and pharmacy dispensing sheets from the
inpatient (ICU and CCU), outpatient (male and
female emergency wards) and pharmacy departments
were reviewed for HRAs by six senior pharmacy students,
who had received formal training in clinical research
and data collection, under the direct supervision of the
ﬁrst author (AH). For the purpose of this study, HRAs
referred to ‘medical abbreviations, dose designations,
drug names, or symbols considered unsafe and likely to
result in misinterpretation.’ These were identiﬁed on
the basis of the ISMP’s list of error-prone abbreviations
by a team of experienced pharmacists based on hospital
usage.13 At ﬁrst, 62 abbreviations were selected, but
these were later narrowed down to 32 items, based on
the frequency of use and severity of the consequences.
Details of abbreviations are listed in table 1.
Sample size
The sample size for this study was estimated on the basis
of the method previously adopted by Abushaiqa et al.12
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Table 1 List of high-risk abbreviations used in this study
High-risk item Intended meaning Possible misinterpretation Preferred correction
Abbreviations
1. µg Microgram mg Write ‘mcg’
2. BT Bedtime BID (twice daily) Use ‘bedtime’
3. cc Cubic centimetres u (units) Use ‘mL’
4. D/C Discharge or
discontinue
Either one Use ‘discharge’ or
‘discontinue’
5. IJ Injection IV or intrajugular Injection
6. HS Bedtime or
half-strength
Either one Use ‘bedtime’ or
‘half-strength’
7. IU International units IV or 10 (ten) Use ‘units’
8. o.d. or OD Once daily Right eye, leading to oral liquid
instilled in to the eye
Use ‘daily’
9. q.d. or QD Every day q.i.d.(four times daily) Use ‘daily’
10. q.o.d. or QOD Every other day q.d. or q.i.d. Use ‘every other day’
11. SC, SQ, sub q Subcutaneous SC as SL (sublingual), SQ as ‘5
every’, q as ‘every’
Use ‘subcut’ or
‘subcutaneously’
12. ss Sliding scale (insulin)
or 1/2
‘55’ Spell out ‘sliding scale’ or
use ‘one-half’ or ‘1/2’
13. U or u
Dose designations and other information
14. Trailing zero after a decimal
point (eg, 1.0 mg)
1 mg 10 mg if the decimal point is not
seen
Express in whole numbers
15. No leading zero before a
decimal point (eg, 0.5 mg)
0.5 mg 5 mg if the decimal point is not
seen
Use zero before the
decimal point
16. Drug name and dose run
together, especially for “L”
ended drugs (eg,
Tegretol300 mg)
Tegretol 300 mg Tegretol 1300 mg Place enough space
between the drug, dose,
and unit
17. Numerical dose and unit of
measure run together (eg,
10 mg, 100 mL)
10 mg, 100 mL The ‘m’ might be mistaken as a
zero or two zeros
Place enough space
between the dose and unit
18. Unit abbreviations with a
period (eg, mg. or mL.)
mg, mL The ‘period’ might be mistaken
as ‘1’
Use mg, mL, etc without a
period
19. Large doses without properly
placed commas (eg, 100 000
units)
100 000 units The ‘100 000’ might be mistaken
as ‘10 000’
Use commas for doses
above ‘1000’ or write ‘100
thousand’ instead
20. ASA Aspirin or
acetylsalicylic acid
5-ASA (5-aminosalicylic acid or
mesalazine) or azathioprine
Use ‘aspirin’
21. HCL Hydrochloric acid or
hydrochloride
The ‘H’ is misinterpreted as
‘K’—potassium chloride
Use complete drug name
unless expressed as a
drug salt
22. HCT Hydrocortisone Hydrochlorothiazide Use complete drug name
23. HCTZ Hydrochlorothiazide Hydrocortisone seen as HCT
250 mg
Use complete drug name
24. MgSO4 Magnesium sulfate Morphine sulfate Use complete drug name
25. MS, MSO4 Morphine sulfate Magnesium sulfate Use complete drug name
26. MTX Methotrexate Mitoxantrone Use complete drug name
27. ZnSO4 Zinc sulfate Morphine sulfate Use complete drug name
Symbols
28. > and < Greater than and less
than
Mistaken as opposite of
intended; ‘<10’ mistaken as ‘40’
Use ‘greater than’ or ‘less
than’
29. / (slash) Separates two doses
or indicates ‘per’
Mistaken as the number ‘1’, eg,
25 units/10 units misread as
‘25 units and 110 units’
Use ‘per’ rather than a
slash mark to separate
doses
30. @ (at sign) At Mistaken as ‘2’ Use ‘at’
31. & (ampersand) And Mistaken as ‘2’ Use ‘and’
32. + (plus sign) Plus or and Mistaken as ‘4’ Use ‘and’
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Taking into account a one-tailed signiﬁcance level
(α=0.05), β=0.2 and incomplete data (20%), the
minimum number of prescriptions required for
before-and-after-intervention assessment was 130.
However, keeping in mind the chances of sampling
errors and limitations of a quasi-experimental single
group pretest post-test design, it was decided to review
all the prescriptions for at least 1 month before and
after the intervention.
Study instruments
A standardised, structured data collection form was
designed on the basis of the criteria presented under
the quality indicators developed by the New South Wales
Therapeutic Advisory Group and Clinical Excellence
Commission.15 Section one of the questionnaire gath-
ered information about patient demographics, section
two gathered information about the prescribing source
and prescriber’s name, and ﬁnally the third section con-
sisted of the list of HRAs. The content validity of the
tool was assessed by the team members and was piloted
to test its validity on the ﬁrst 20 prescriptions.
Pharmacist intervention
Pretest assessment: This part of the study was designed
to get the baseline data about the incidence of HRAs in
the study setting. The preassessment phase was initiated
in the ﬁrst week of February 2011 and lasted until the
ﬁrst week of March 2011. Data about the HRAs were col-
lected from all handwritten physician orders, medication
administration records and pharmacy dispensing sheets
during the study period.
Educational intervention: After collecting the initial data,
the educational intervention was undertaken from 2 April
to 2 May 2011. The educational intervention was led by an
experienced pharmacist with postgraduate qualiﬁcation in
clinical pharmacy (AH) and assisted by senior pharmacy
students trained by the research team. The educational
intervention was delivered to all healthcare providers and
was designed in accordance with the recommendations of
ISMP13 and the US Food and Drug Administration.14 The
educational tools included in the intervention were:
▸ A printed list of abbreviations on brightly coloured
paper that was inserted into medical records/patient
charts, placed next to all hospital computers and
posted in the patient care area;20 21
▸ Pocket-sized ﬂash cards with the HRA list provided
for all staff;
▸ Laminated copies of the list attached to the back of
the physician’s order divider in medical records;
▸ Patient safety posters given to the hospital wards
explaining the HRAs.
All hospital staff, including physicians, nurses, pharma-
cists and related staff (∼250 people), were requested to
attend a series of educational sessions during the inter-
vention phase. The interactive lectures were delivered by
AH. The lectures highlighted the basic concepts of
medication, prescribing and dispensing errors and nega-
tive consequences of using HRAs in emergency settings.
In addition, methods of avoiding medication errors and
use of HRAs were also discussed. To make sure that all
staff were aware of this campaign, each staff member was
required to sign a form to conﬁrm that they had
received the list and agreed not to use the dangerous
abbreviations. At the end of each session, a certiﬁcate of
attendance was issued to each staff member.
Additionally, the research team distributed educational
tools (laminated pocket cards with the HRA list, pens
and tea mugs with an abbreviation logo) to all partici-
pants at the end of the lectures.22
Post-test assessment
In the ﬁnal phase, postintervention, all prescriptions
written during the 1 month ( June to July 2011) from
Table 2 Prescriptions with high-risk abbreviations across three sources categorised according to whether they were
preintervention or postintervention
Preintervention Postintervention
Prescription source
Number of
patients
Incidence*
(%)
Number of
patients
Incidence*
(%)
IRD†
(%)
χ2
(df=1)
Hospital emergency wards (M/F
emergency departments)
42 40.9 (90/220) 30 10.7 (15/140) 73.8 37.756‡
Pharmacy department 220 72.7 (160/220) 178 39.3 (70/178) 45.9 45.001‡
Inpatient settings 220 47.3 (104/220) 180 23.3 (42/180) 50.7 24.479‡
Total 482 53.6 (354/660) 388 25.5 (127/498) 52.4 92.517‡
*Incidence of high-risk abbreviation use calculated by using the equation:
Incidence ¼ Number of prescriptionswith at least onehigh risk abbreviation
Total number of prescriptions found in eachsource
 100
†Incidence rate decrease (IRD) can be calculated by
IRD ¼ jPost intervention incidence Pre intervention incidencej
Pre intervention incidence  100
‡p=0.001 (statistically significant at α=0.05).
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the same three sources were re-evaluated using the same
data collection form to assess the use of HRAs.
Data analysis
All the data collected were entered into Microsoft Excel
2010 (Microsoft Corporation, Redmond, Washington, USA)
and PASW Statistics V.18 (SPSS-IBM Co, Chicago, Illinois,
USA). Descriptive statistics were used to calculate the inci-
dence of HRAs. A χ2 test for proportions was employed to
analyse the difference in the incidence of HRAs with a sig-
niﬁcance level (α) of 0.05 using a two-tailed test.
RESULTS
A total of 660 prescriptions for 482 patients from three
sources (emergency wards, the pharmacy department
and inpatient ICU and CCU settings) were collected
before the educational interventions, and 498 prescrip-
tions (from 388 patient records) after the interventions.
Details of all prescriptions with at least one HRA and
the incidence of each HRA are set out in table 2. The
highest incidence of HRA was found among discharge
prescriptions and dispensing records kept in the phar-
macy department (72.7%), followed by prescriptions
from inpatient settings (47.3%) and prescription charts
from hospital emergency wards (40.9%). With respect to
speciﬁc high-risk abbreviations, 14 of the 32 selected
abbreviations were identiﬁed, as summarised in table 3.
The ﬁve most common abbreviations recorded prior to
the interventions were ‘IJ for injection’ (28.6%), ‘SC for
subcutaneous’ (17.4%), drug name and dose running
together (9.7%), ‘OD for once daily’ (5.8%) and ‘D/C
for discharge’ (4.3%). Although these abbreviations
were noted across all three prescription sources, the
abbreviation ‘SC’ occurred most frequently in hospital
emergency services (15.4%) and inpatient settings
(25.9%), while ‘IJ’ was found principally in the phar-
macy department (52.7%).
After the intervention, the relative distribution of
HRAs remained similar (ie, the pharmacy department
remained the highest, etc), but there was a statistically
signiﬁcant reduction in the incidence of HRAs across all
three sources: the pharmacy department (72.7% vs
39.3%), inpatient settings (47.3% vs 23.3%) and emer-
gency wards (40.9% vs 10.7%) (all p=0.001). The overall
incidence of HRAs also decreased signiﬁcantly by 52%
after the interventions (53.6% vs 25.5%; p=0.001).
DISCUSSION
This is perhaps the ﬁrst study of its kind in the Gulf
region, particularly in Saudi Arabia, which evaluated the
effectiveness of a pharmacist-led educational interven-
tion to reduce the incidence of HRAs in acute care set-
tings. Another study conducted in a large university
hospital in Riyadh, Saudi Arabia reported a 65%
Table 3 Frequencies of high-risk abbreviations recorded in prescriptions across three sources
Frequency of high-risk abbreviations* (%)
Hospital emergency
wards
Pharmacy
department In-patient settings Total
High-risk abbreviation
Pre-int
(n=220)
Post-int
(n=140)
Pre-int
(n=220)
Post-int
(n=178)
Pre-int
(n=220)
Post-int
(n=180)
Pre-int
(n=660)
Post-int
(n=498)
1. µg 3.6 1.4 0 0 0 0 1.2 0.4
2. D/C 5.4 0 7.7 1.6 0 0 4.3 0.5
3. IJ 8.1 0 52.7 22.4 25 10 28.6 10.8
4. IU 0.9 0 5.4 0 0 0 2.1 0
5. o.d. or OD 7.7 0 7.7 1.1 2.2 0.5 5.8 0.5
6. SC 15.4 10.7 10.9 11.2 25.9 5.5 17.4 9.1
7. U or u 3.6 1.4 1.8 0 2.7 3.8 2.7 1.7
8. No leading zero
before a decimal point
0.9 0 2.2 1.6 0 0 1.0 0.5
9. Drug name and
dose run together -‘L’
ended drugs
11.3 3.5 9.0 2.8 9.0 5.5 9.7 3.9
10. Numerical dose
and unit of measure
run together
4.5 1.4 2.2 5.6 2.2 0 2.9 2.3
11. ASA 1.8 0 0 0 0.9 0 0.9 0
12. / (slash) 4.5 3.5 6.8 3.3 0 0 3.7 2.2
13. & (ampersand) 3.6 0 2.2 0 0 0 1.9 0
14.+ (plus sign) 1.8 0 0 0 0 0 0.6 0
*Frequency of high-risk abbreviations in prescriptions computed by
Frequency ¼ Number of high risk abbreviations
Total number of prescriptions found in each source
 100
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decrease in use of unsafe abbreviations following the
implementation of an educational intervention.23
The ISMP recommends that reduction of HRAs is one
of the most effective strategies to improve standards of
medication safety.13 This is especially because HRAs are
closely linked to medical errors and life-threatening con-
sequences but can be easily avoided when prescribing.8
In routine practice, the pharmacist occupies a key pos-
ition where errors can be identiﬁed before medication is
dispensed to patients or dispatched to a ward. It is vital,
however, to educate the healthcare team to adopt a
safety culture that aims to avoid or minimise the use of
HRAs. In this study, it was seen that the overall incidence
of HRAs was 53.6%, which is higher than that reported
by other studies.20
The educational interventions led by the pharmacist
have been shown to have a positive effect on the behav-
iour of physicians with respect to the use of HRAs and
signiﬁcantly reduced the overall incidence, which is in
line with the ﬁndings of other studies.20 23 24 Taylor
et al20 reported a 41% decrease in the incidence rate of
HRAs following a pharmacist-led intervention (31.8% vs
18.7%). Moreover, Abushaiqa et al12 reported six abbre-
viations and dosage designations deemed unsafe, includ-
ing ‘U for units’, ‘μg for microgram’, ‘TIW for three
times a week’, ‘the degree (°) for hour’, trailing zeros
after a decimal point and the lack of a leading zero
before a decimal. Of these, three items were also identi-
ﬁed in our study as well: ‘U for units’, ‘μg for micro-
gram’ and the lack of a leading zero before a decimal. A
possible explanation might be that these abbreviations
are widely accepted; many prescribers have used them
for decades and are reluctant to change.24 Although
only 14 of 32 surveyed items were actually identiﬁed as
occurring in this study, this does not imply that the
remaining abbreviations are unimportant, as they might
nonetheless be occasionally used by healthcare
professionals.
Since the highest incidence of HRAs was noted in the
discharge prescriptions and dispensing records kept in
the Pharmacy department, pharmacists, as the last point
of contact, are the key professionals for the prevention
of medication errors. Meyer suggested that ongoing edu-
cational programmes, follow-up reminders and feedback
to prescribers can greatly improve prescribers’
prescription-writing habits.25 Accordingly, pharmacists
should participate in an educational programme to help
improve their prescription-writing skills with the use of
acceptable abbreviations and feedback any medication
errors on a regular basis.
CLINICAL IMPLICATIONS
There are a number of clinical implications for this study.
First, the incidence of using HRAs in an acute care setting
is alarmingly high, which may lead to medication errors,
necessitating an action plan to discourage the use of
HRAs. Second, a pharmacist-led educational intervention
can potentially reduce the use of HRAs in clinical practice.
Third, the use of handwritten prescriptions should be dis-
couraged as they are sometimes illegible and prone to mis-
interpretation. Finally, healthcare professionals in Saudi
Arabia are predominantly expatriates with a diverse educa-
tional, cultural and linguistic background, so it is import-
ant to develop safe prescribing guidelines at the local and
national levels to ensure patient safety. In the USA, many
organisations24 26–28 dealing with patient safety have tried
to discourage the use of error-prone abbreviations and
dose expressions in healthcare settings over two decades,
but the prescribing practice is only decreasing slowly.
Similarly, in the UK, prescribers are encouraged to use
English in place of Latin abbreviations.29 Interestingly, ‘o.
d. or OD for every day’ and ‘o.n. or ON for every night’
are considered unsafe but are nonetheless commonly
used in routine clinical practice. Educational interventions
on a periodic basis can be one of the ways to modify pre-
scriber behaviour and limit the use of HRAs.
LIMITATION
The ﬁndings of this study should be considered in the
context of the study design limitations. There are two
main limitations. First, randomised controlled trials
(RCTs) are considered as the gold standard to evaluate
the effectiveness of an intervention.19 However,
quasi-experimental designs are ideal when conducting
RCTs is either logistically or ethically not possible.18 We
could not conduct an RCT due to the unavailability of a
suitable control group, as this emergency centre is spe-
ciﬁcally designated for pilgrims only and there was no
other such facility in the region. Owing to the lack of
randomisation and control groups, several threats to the
internal validity of before-and-after quasi-experimental
studies have been reported in the literature including
maturation, the Hawthorne effect, regression to the
mean, dropout and testing.19 Second, the number of
prescriptions reviewed during the post-intervention
phase was about 25% less than that during the preinter-
vention phase. As mentioned above, the study site is spe-
ciﬁcally designated for pilgrims and there are seasonal
variations in the number of pilgrims. The decrease in
patient numbers may have contributed to the decrease
in the incidence of HRAs observed in the post-
intervention phase. However, the incidence of using
HRAs was reduced by 52%, which is signiﬁcantly more
than the decrease in the number of prescriptions seen
in the post-intervention phase, suggesting a positive
intervention effect.
CONCLUSION
Educational interventions led by pharmacists can be
effective in reducing the use of HRAs by physicians and
other healthcare providers, leading to a decrease in
medication errors. In this study setting, the use of HRAs
was noted to be high, which can compromise patient
safety; therefore, it is essential for the regional and
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national Saudi health authorities to devise and imple-
ment policies and protocols to discourage the use of
HRAs. Future research should explore the effectiveness
of pharmacist-led interventions in reducing the use of
HRAs in emergency and other settings using well-
designed randomised controlled trials.
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